Review



ctx tna2  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 98
      Buy from Supplier

    Structured Review

    ATCC ctx tna2
    Ctx Tna2, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 4314 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ctx tna2/product/ATCC
    Average 98 stars, based on 4314 article reviews
    ctx tna2 - by Bioz Stars, 2026-05
    98/100 stars

    Images



    Similar Products

    ctx tna2  (ATCC)
    98
    ATCC ctx tna2
    Ctx Tna2, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ctx tna2/product/ATCC
    Average 98 stars, based on 1 article reviews
    ctx tna2 - by Bioz Stars, 2026-05
    98/100 stars
    		  Buy from Supplier
    c6 atcc ccl 107  (ATCC)
    96
    ATCC c6 atcc ccl 107
    C6 Atcc Ccl 107, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c6 atcc ccl 107/product/ATCC
    Average 96 stars, based on 1 article reviews
    c6 atcc ccl 107 - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    ctx tna2 astrocyte  (ATCC)
    96
    ATCC ctx tna2 astrocyte
    A In vitro release study of piracetam loaded solid lipid nanoparticle-2 (PSLN-2) in phosphate-buffered saline (PBS), pH 7.4. The study depicted a sustained release profile of piracetam from PSLN-2, whereas the burst release was observed for plain piracetam; B Percentage of inhibition of the DPPH scavenging activity by ascorbic acid, piracetam and PSLN-2 (IC 50 :18.92 ± 1.7, 27.8 ± 1.18, and 23.43 ± 0.21 μg/mL); C Percentage of inhibition of the ABTS scavenging activity by ascorbic acid, piracetam and PSLN-2 (IC 50 :13.34 ± 1.23, 2 3.9 ± 1.56, and 18.1 ± 1.04 μg/mL). All the data are represented as Mean ± SD where n = 3; D In vitro cytotoxicity study of PSLN-2 on CTX <t>TNA2</t> astrocyte (CRL-2006) and HT22 mice neuronal hippocampus cell line (SCC129). Data showed biocompatible nature of experimental PSLN-2 with more than 85% cell viability at the highest tested concentrations. Data represented as Mean ± SD, where n = 3. Student’s t-test * p < 0.05
    Ctx Tna2 Astrocyte, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ctx tna2 astrocyte/product/ATCC
    Average 96 stars, based on 1 article reviews
    ctx tna2 astrocyte - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    type i cell line  (ATCC)
    96
    ATCC type i cell line
    A In vitro release study of piracetam loaded solid lipid nanoparticle-2 (PSLN-2) in phosphate-buffered saline (PBS), pH 7.4. The study depicted a sustained release profile of piracetam from PSLN-2, whereas the burst release was observed for plain piracetam; B Percentage of inhibition of the DPPH scavenging activity by ascorbic acid, piracetam and PSLN-2 (IC 50 :18.92 ± 1.7, 27.8 ± 1.18, and 23.43 ± 0.21 μg/mL); C Percentage of inhibition of the ABTS scavenging activity by ascorbic acid, piracetam and PSLN-2 (IC 50 :13.34 ± 1.23, 2 3.9 ± 1.56, and 18.1 ± 1.04 μg/mL). All the data are represented as Mean ± SD where n = 3; D In vitro cytotoxicity study of PSLN-2 on CTX <t>TNA2</t> astrocyte (CRL-2006) and HT22 mice neuronal hippocampus cell line (SCC129). Data showed biocompatible nature of experimental PSLN-2 with more than 85% cell viability at the highest tested concentrations. Data represented as Mean ± SD, where n = 3. Student’s t-test * p < 0.05
    Type I Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/type i cell line/product/ATCC
    Average 96 stars, based on 1 article reviews
    type i cell line - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    suh jw 2006 catalytic domain  (ATCC)
    96
    ATCC suh jw 2006 catalytic domain
    A In vitro release study of piracetam loaded solid lipid nanoparticle-2 (PSLN-2) in phosphate-buffered saline (PBS), pH 7.4. The study depicted a sustained release profile of piracetam from PSLN-2, whereas the burst release was observed for plain piracetam; B Percentage of inhibition of the DPPH scavenging activity by ascorbic acid, piracetam and PSLN-2 (IC 50 :18.92 ± 1.7, 27.8 ± 1.18, and 23.43 ± 0.21 μg/mL); C Percentage of inhibition of the ABTS scavenging activity by ascorbic acid, piracetam and PSLN-2 (IC 50 :13.34 ± 1.23, 2 3.9 ± 1.56, and 18.1 ± 1.04 μg/mL). All the data are represented as Mean ± SD where n = 3; D In vitro cytotoxicity study of PSLN-2 on CTX <t>TNA2</t> astrocyte (CRL-2006) and HT22 mice neuronal hippocampus cell line (SCC129). Data showed biocompatible nature of experimental PSLN-2 with more than 85% cell viability at the highest tested concentrations. Data represented as Mean ± SD, where n = 3. Student’s t-test * p < 0.05
    Suh Jw 2006 Catalytic Domain, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/suh jw 2006 catalytic domain/product/ATCC
    Average 96 stars, based on 1 article reviews
    suh jw 2006 catalytic domain - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    s tennessee k4642  (ATCC)
    96
    ATCC s tennessee k4642
    A In vitro release study of piracetam loaded solid lipid nanoparticle-2 (PSLN-2) in phosphate-buffered saline (PBS), pH 7.4. The study depicted a sustained release profile of piracetam from PSLN-2, whereas the burst release was observed for plain piracetam; B Percentage of inhibition of the DPPH scavenging activity by ascorbic acid, piracetam and PSLN-2 (IC 50 :18.92 ± 1.7, 27.8 ± 1.18, and 23.43 ± 0.21 μg/mL); C Percentage of inhibition of the ABTS scavenging activity by ascorbic acid, piracetam and PSLN-2 (IC 50 :13.34 ± 1.23, 2 3.9 ± 1.56, and 18.1 ± 1.04 μg/mL). All the data are represented as Mean ± SD where n = 3; D In vitro cytotoxicity study of PSLN-2 on CTX <t>TNA2</t> astrocyte (CRL-2006) and HT22 mice neuronal hippocampus cell line (SCC129). Data showed biocompatible nature of experimental PSLN-2 with more than 85% cell viability at the highest tested concentrations. Data represented as Mean ± SD, where n = 3. Student’s t-test * p < 0.05
    S Tennessee K4642, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/s tennessee k4642/product/ATCC
    Average 96 stars, based on 1 article reviews
    s tennessee k4642 - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    andes and craig  (ATCC)
    96
    ATCC andes and craig
    A In vitro release study of piracetam loaded solid lipid nanoparticle-2 (PSLN-2) in phosphate-buffered saline (PBS), pH 7.4. The study depicted a sustained release profile of piracetam from PSLN-2, whereas the burst release was observed for plain piracetam; B Percentage of inhibition of the DPPH scavenging activity by ascorbic acid, piracetam and PSLN-2 (IC 50 :18.92 ± 1.7, 27.8 ± 1.18, and 23.43 ± 0.21 μg/mL); C Percentage of inhibition of the ABTS scavenging activity by ascorbic acid, piracetam and PSLN-2 (IC 50 :13.34 ± 1.23, 2 3.9 ± 1.56, and 18.1 ± 1.04 μg/mL). All the data are represented as Mean ± SD where n = 3; D In vitro cytotoxicity study of PSLN-2 on CTX <t>TNA2</t> astrocyte (CRL-2006) and HT22 mice neuronal hippocampus cell line (SCC129). Data showed biocompatible nature of experimental PSLN-2 with more than 85% cell viability at the highest tested concentrations. Data represented as Mean ± SD, where n = 3. Student’s t-test * p < 0.05
    Andes And Craig, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/andes and craig/product/ATCC
    Average 96 stars, based on 1 article reviews
    andes and craig - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    A In vitro release study of piracetam loaded solid lipid nanoparticle-2 (PSLN-2) in phosphate-buffered saline (PBS), pH 7.4. The study depicted a sustained release profile of piracetam from PSLN-2, whereas the burst release was observed for plain piracetam; B Percentage of inhibition of the DPPH scavenging activity by ascorbic acid, piracetam and PSLN-2 (IC 50 :18.92 ± 1.7, 27.8 ± 1.18, and 23.43 ± 0.21 μg/mL); C Percentage of inhibition of the ABTS scavenging activity by ascorbic acid, piracetam and PSLN-2 (IC 50 :13.34 ± 1.23, 2 3.9 ± 1.56, and 18.1 ± 1.04 μg/mL). All the data are represented as Mean ± SD where n = 3; D In vitro cytotoxicity study of PSLN-2 on CTX TNA2 astrocyte (CRL-2006) and HT22 mice neuronal hippocampus cell line (SCC129). Data showed biocompatible nature of experimental PSLN-2 with more than 85% cell viability at the highest tested concentrations. Data represented as Mean ± SD, where n = 3. Student’s t-test * p < 0.05

    Journal: Discover Nano

    Article Title: Solid lipid nanoparticles enhance piracetam’s neuroprotective action in streptozotocin-induced cognitive dysfunction

    doi: 10.1186/s11671-026-04528-3

    Figure Lengend Snippet: A In vitro release study of piracetam loaded solid lipid nanoparticle-2 (PSLN-2) in phosphate-buffered saline (PBS), pH 7.4. The study depicted a sustained release profile of piracetam from PSLN-2, whereas the burst release was observed for plain piracetam; B Percentage of inhibition of the DPPH scavenging activity by ascorbic acid, piracetam and PSLN-2 (IC 50 :18.92 ± 1.7, 27.8 ± 1.18, and 23.43 ± 0.21 μg/mL); C Percentage of inhibition of the ABTS scavenging activity by ascorbic acid, piracetam and PSLN-2 (IC 50 :13.34 ± 1.23, 2 3.9 ± 1.56, and 18.1 ± 1.04 μg/mL). All the data are represented as Mean ± SD where n = 3; D In vitro cytotoxicity study of PSLN-2 on CTX TNA2 astrocyte (CRL-2006) and HT22 mice neuronal hippocampus cell line (SCC129). Data showed biocompatible nature of experimental PSLN-2 with more than 85% cell viability at the highest tested concentrations. Data represented as Mean ± SD, where n = 3. Student’s t-test * p < 0.05

    Article Snippet: CTX TNA2 astrocyte, type I cell line (CRL-2006) was collected from American Type Culture Collection, Manassas, VA.

    Techniques: In Vitro, Saline, Inhibition, Activity Assay